Clinical pharmacology of vecuronium and atracurium.
Vecuronium and atracurium provide addition flexibility to the clinician using neuromuscular blocking drugs. The shorter duration of action, lack of significant cardiovascular effects, and the lack of dependence on the kidney for elimination provide clinical advantages over, or alternatives to, currently available nondepolarizing neuromuscular blocking drugs.
D000136:Acid-Base Equilibrium; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000758:Anesthesia; D000773:Anesthesia, Obstetrical; D001279:Atracurium; D002315:Cardiopulmonary Bypass; D002319:Cardiovascular System / Q000187:drug effects; D002585:Cesarean Section; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007546:Isoquinolines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology; D009466:Neuromuscular Blocking Agents / Q000494:pharmacology*; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D011247:Pregnancy; D013390:Succinylcholine / Q000494:pharmacology; D013997:Time Factors; D014673:Vecuronium Bromide
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D001279:Atracurium; D009388:Neostigmine; D014673:Vecuronium Bromide; D013390:Succinylcholine; D010197:Pancuronium